In a strategic move to strengthen its presence in rare endocrinology diseases, Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a transaction valued at approximately US$2.9 B. The deal provides Neurocrine with immediate commercial advantage through Soleno’s lead product, Vykat™ XR (diazoxide choline extended release), which is the first and only treatment approved in the US for hyperphagia associated with Prader–Willi Syndrome (PWS). The acquisition complements Neurocrine’s emerging endocrinology portfolio and diversifies its revenue base, thereby enhancing both therapeutic breadth and long term growth prospects.